Clinical trial
Chimeric Antigen Receptor (CAR)-T Cells to Target GD2 for Diffuse Midline Glioma
NCT05544526 is registered in ClinicalTrials.gov with University College, London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Chimeric Antigen Receptor (CAR)-T Cells to Target GD2 for Diffuse Midline Glioma
- Lead sponsor
- University College, London
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 15, 2023
- Completion date
- August 31, 2042
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse midline glioma, h3 k27m-mutant